A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands
Objectives: To describe the real-world effectiveness and safety of bosutinib in patients with chronic myeloid leukemia (CML). Methods: This was a multi-center, retrospective, non-interventional chart review study conducted in 10 hospitals in the United Kingdom and the Netherlands. Results: Eighty-seven patients were included. Bosutinib was the third-line tyrosine kinase inhibitor (TKI) in 33 (38%) and fourth-line in 44 (51%) patients. Median treatment duration was 15.6 months. Among 84 patients in chronic phase (CP) at baseline, 26 (31%) switched to bosutinib due to resistance and 57 (68%) due... Mehr ...
Verfasser: |
Claudiani, Simone
Janssen, Jeroen J. W. M.
Byrne, Jenny
Smith, Graeme
Blijlevens, Nicole
Raghavan, Manoj
Smith, Matthew
Clark, Richard E.
Mclain-Smith, Susan
Carter, Angela M.
Milojkovic, Dragana
Apperley, Jane F. |
Dokumenttyp: |
Artikel |
Erscheinungsdatum: |
2022 |
Reihe/Periodikum: |
Claudiani , S , Janssen , J J W M , Byrne , J , Smith , G , Blijlevens , N , Raghavan , M , Smith , M , Clark , R E , Mclain-Smith , S , Carter , A M , Milojkovic , D & Apperley , J F 2022 , ' A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands ' , European Journal of Haematology , vol. 109 , no. 1 , pp. 90-99 . https://doi.org/10.1111/ejh.13775 |
Sprache: |
Englisch |
Permalink: |
https://search.fid-benelux.de/Record/base-28801966 |
Datenquelle: |
BASE;
Originalkatalog |
Powered By: |
BASE |
Link(s) :
|
https://research.vumc.nl/en/publications/36f128f5-c6cf-4994-984e-b4f481900861 |